sorafenib has been researched along with calcitriol in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (calcitriol) | Trials (calcitriol) | Recent Studies (post-2010) (calcitriol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 16,107 | 1,224 | 3,710 |
| Protein | Taxonomy | sorafenib (IC50) | calcitriol (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0093 | |
| Vitamin D3 receptor | Homo sapiens (human) | 0.3401 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.0093 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Tan, W | 1 |
| Aizic, A; Fliss, DM; Izkhakov, E; Knoll, E; Kohen, F; Sharon, O; Somjen, D; Stern, N | 1 |
2 review(s) available for sorafenib and calcitriol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
1 other study(ies) available for sorafenib and calcitriol
| Article | Year |
|---|---|
A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adolescent; Adult; Aged; Antineoplastic Agents; Case-Control Studies; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans; Isoflavones; Male; Middle Aged; Receptors, Calcitriol; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Vitamin D; Young Adult | 2018 |